Compare VRCA & RGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRCA | RGS |
|---|---|---|
| Founded | 2013 | 1922 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Consumer Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.0M | 72.6M |
| IPO Year | 2018 | 1994 |
| Metric | VRCA | RGS |
|---|---|---|
| Price | $3.55 | $24.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $13.83 | N/A |
| AVG Volume (30 Days) | ★ 59.0K | 13.2K |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.18 |
| Revenue | $35,577,000.00 | ★ $224,485,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $60.79 | $1.68 |
| P/E Ratio | ★ N/A | $133.72 |
| Revenue Growth | ★ 370.22 | 6.83 |
| 52 Week Low | $3.08 | $19.31 |
| 52 Week High | $9.82 | $32.00 |
| Indicator | VRCA | RGS |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 31.19 |
| Support Level | $3.30 | $24.00 |
| Resistance Level | $5.94 | $29.05 |
| Average True Range (ATR) | 0.30 | 1.32 |
| MACD | 0.04 | -0.67 |
| Stochastic Oscillator | 45.87 | 8.26 |
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.
Regis Corporation franchises, owns, and operates hair care salons, mainly in North America, with licensed locations in the U.K. Its salons provide haircutting, styling, shampooing and conditioning, hair coloring and related services, and also sell hair care and beauty products. The company's primary brands include Supercuts, SmartStyle, Cost Cutters, First Choice Haircutters and Roosters. Its operating segments are Franchise and Company-Owned, with the majority of its revenue generated from the Franchise segment.